SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

July 14, 2010 08:30 ET

UV Flu Technologies to Be Profiled Within Influential UK Industry Publication "The Public Service Review"

CENTERVILLE, MA--(Marketwire - July 14, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the ViraTech UV-400 will be profiled in the prestigious opinion and analysis industry publication The Public Service Review. The publishers have advised that print distribution commences today with an online version available within a few days.

Published in the UK, The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.

"The Public Service Review is a sector specific publication and website that is highly selective regarding content, as it is distributed to thousands of key decision makers in the health-care field in the UK, as well as all of Europe," said Jack Lennon, President of UV Flu Technologies. "Health care executives, doctors, ministers of health, as well as purchasing executives, all use this publication for reference and it definitely influences their purchasing decisions.

"Europe is projected to be a big market for us, as respiratory problems due to poor indoor air quality have become a significant issue, especially institutionally," stated Mr. Lennon. He further comments, "We are also factoring in the spread of MRSA, a bacteria that has become impervious to antibiotics, and whose transmission has become epidemic in many health care facilities around the world. Our inclusion as one of the only air purifiers in the Review's section on Infection Protection and Control is extraordinarily good news and excellent brand positioning for the Company."

Mr. Lennon continues, "The UV-400 kills MRSA, and other Hospital Associated Infections ("HAI") that have become a very serious problem in the United Kingdom, and parts of Europe. Hospital personnel including doctors have experienced severe illnesses from these bacteria and as a result have incurred significant staffing issues and costs. Patients are going into hospitals for simple procedures and some are becoming very sick due to MRSA which is ultimately damaging to both the reputation of physicians and institutions alike. Notwithstanding the very tragic impact to the families involved, this can sometimes lead to expensive litigation and other secondary costs. UV Flu hopes to make a positive contribution towards fighting the spread of MRSA and other HAIs," said Mr. Lennon.

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: For sales:

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: For sales:

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Contact Information